Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Short term Debt (2016 - 2019)

Fate Therapeutics (FATE) has disclosed Short term Debt for 8 consecutive years, with $13.9 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Short term Debt rose 326.84% year-over-year to $13.9 million, compared with a TTM value of $13.9 million through Sep 2019, up 326.84%, and an annual FY2018 reading of $2.4 million, changed N/A over the prior year.
  • Short term Debt was $13.9 million for Q3 2019 at Fate Therapeutics, up from $5.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $13.9 million in Q3 2019 and bottomed at $758000.0 in Q1 2018.
  • Average Short term Debt over 5 years is $5.9 million, with a median of $6.0 million recorded in 2015.
  • The sharpest move saw Short term Debt soared 962.85% in 2015, then plummeted 90.12% in 2018.
  • Year by year, Short term Debt stood at $7.7 million in 2015, then increased by 6.48% to $8.2 million in 2016, then fell by 6.3% to $7.7 million in 2017, then crashed by 68.22% to $2.4 million in 2018, then soared by 471.45% to $13.9 million in 2019.
  • Business Quant data shows Short term Debt for FATE at $13.9 million in Q3 2019, $5.4 million in Q2 2019, and $3.9 million in Q1 2019.